Comparative Pharmacology
Head-to-head clinical analysis: FLUOR OP versus OZURDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOR OP versus OZURDEX.
FLUOR-OP vs OZURDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammatory responses.
Dexamethasone, a potent corticosteroid, reduces inflammation by inhibiting multiple inflammatory cytokines including prostaglandins, leukotrienes, and interleukins. It suppresses the migration of polymorphonuclear leukocytes and reverses increased capillary permeability. The mechanism involves binding to the glucocorticoid receptor, leading to regulation of gene expression that reduces production of inflammatory mediators.
2 drops of 0.1% solution into the affected eye(s) every 15 minutes for 4 doses, then every 30 minutes for 2 doses, then every 1-2 hours for 24-48 hours, then tapering over 1-2 weeks; alternatively, 0.5 cm ribbon of 0.05% ointment into the conjunctival sac 4-6 times daily.
Single intravitreal implant of 0.7 mg (dexamethasone 700 mcg) in the affected eye; repeat dosing no sooner than 3 months after the prior implant.
None Documented
None Documented
Terminal elimination half-life is 3-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
In the vitreous humor, the half-life is approximately 5-7 months following intravitreal implant administration. Systemic half-life is negligible due to low systemic exposure.
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with the remainder as metabolites (glucuronide conjugates) via urine; fecal elimination is minimal (<5%).
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (≈70%) and urine (≈30%). Less than 1% excreted as unchanged drug.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid